Channick RN, Sitbon O, Barst RJ, et al: Endothelin receptor antagonists in pulmonary arterial hypertension
Pulmonary arterial hypertension
may be idiopathic and sporadic (IPAH), familial (FPAH), or associated with (APAH) connective tissue diseases, congenital systemic to pulmonary shunts, portal hypertension, HIV, drugs including anorexigens or cocaine, and other disorders (Table 1).
Tracleer(tm) today - Approved in Pulmonary arterial hypertension
Tracleer(tm), the first orally available dual endothelin receptor antagonist, is currently approved and available in the United States, the European Union (Germany and UK, others to follow), Canada and Switzerland for the treatment of Pulmonary Arterial Hypertension
, a chronic life-threatening condition that severely compromises the function of the lungs and heart.
A review of the Pulmonary Arterial Hypertension
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pattern of arterial duct shunt of all cases was left- to-right and they all developed moderate or severe pulmonary arterial hypertension
(pulmonary arterial systolic pressure 59 mmHg~87 mmHg).
In PATENT-1, a 36-m improvement in 6-minute walk distance was noted in patients with pulmonary arterial hypertension
It is interesting to note that arterial hypertension
was one of the main predisposing factors for stroke as in the young, as in the elderly.
Powerful links were also seen between psoriasis and arterial hypertension
, hyperlipoproteinemia, coronary heart disease, metabolic syndrome, cigarette smoking, and alcoholism.
Texas Biotechnology also has two highly selective endothelin A receptor antagonists in clinical development for pulmonary arterial hypertension
and congestive heart failure.
com/research/n92gtn/pulmonary) has announced the addition of GlobalData's new report "Pulmonary Arterial Hypertension
Global Clinical Trials Review, H2, 2012" to their offering.
M2 PHARMA-July 4, 2017-Cardiome files TREVYENT NDA with US FDA for pulmonary arterial hypertension
Pharmaceutical company SteadyMed Ltd (NasdaqGM:STDY) revealed on Thursday the completion of the manufacture of all of the Trevyent batches for shelf-life studies needed to support the submission of its NDA for the treatment of Pulmonary Arterial Hypertension
(PAH) in the Q1 2017.
ClickPress, Wed May 14 2014] Pulmonary Arterial Hypertension
- Pipeline Review, H1 2014
Contract award: Medications to treat pulmonary arterial hypertension